Biotech News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis (OCS)OculisCompany update

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a member of the Company’s Executive Committee and Board of Directors. Attachment Notification of managers' transaction - Riad Sherif - 5 October 2026 RSU

Related news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

Stock data

Close
7.87 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States